KR102356433B1 - 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법 - Google Patents

치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법 Download PDF

Info

Publication number
KR102356433B1
KR102356433B1 KR1020187028514A KR20187028514A KR102356433B1 KR 102356433 B1 KR102356433 B1 KR 102356433B1 KR 1020187028514 A KR1020187028514 A KR 1020187028514A KR 20187028514 A KR20187028514 A KR 20187028514A KR 102356433 B1 KR102356433 B1 KR 102356433B1
Authority
KR
South Korea
Prior art keywords
cancer
compound
delete delete
aminopurine
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187028514A
Other languages
English (en)
Korean (ko)
Other versions
KR20180126497A (ko
Inventor
존 에프. 보이랜
고든 엘. 브레이
엘렌 필바로프
로버트 허바드
데이비드 미코론
헤더 레이먼
타오 쉬
탐 엠. 트란
토시야 쯔지
릴리 엘. 웡
쉬찬 쉬
단 쥬
Original Assignee
시그날 파마소티칼 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그날 파마소티칼 엘엘씨 filed Critical 시그날 파마소티칼 엘엘씨
Publication of KR20180126497A publication Critical patent/KR20180126497A/ko
Application granted granted Critical
Publication of KR102356433B1 publication Critical patent/KR102356433B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187028514A 2016-04-01 2017-03-31 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법 Active KR102356433B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317412P 2016-04-01 2016-04-01
US62/317,412 2016-04-01
PCT/US2017/025252 WO2017173206A1 (en) 2016-04-01 2017-03-31 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
KR20180126497A KR20180126497A (ko) 2018-11-27
KR102356433B1 true KR102356433B1 (ko) 2022-01-27

Family

ID=59959573

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028514A Active KR102356433B1 (ko) 2016-04-01 2017-03-31 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법

Country Status (15)

Country Link
US (1) US10576085B2 (https=)
EP (1) EP3436018A4 (https=)
JP (1) JP7014731B2 (https=)
KR (1) KR102356433B1 (https=)
CN (1) CN109069512B (https=)
AU (1) AU2017241837B2 (https=)
BR (1) BR112018070163A2 (https=)
CA (1) CA3018986A1 (https=)
CL (1) CL2018002787A1 (https=)
EA (1) EA039392B1 (https=)
IL (1) IL262007B2 (https=)
MX (1) MX379513B (https=)
NZ (1) NZ746554A (https=)
SG (2) SG11201808388QA (https=)
WO (1) WO2017173206A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
BR112018068676A2 (pt) 2016-03-31 2019-01-15 Janssen Pharmaceuticals Inc derivados de indol substituídos como inibidores da replicação viral do dengue
BR112018069601A2 (pt) 2016-03-31 2019-01-29 Janssen Pharmaceuticals Inc derivados de indolina substituídos como inibidores da replicação viral da dengue
HUE056631T2 (hu) 2016-04-01 2022-02-28 Signal Pharm Llc (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
EP3630723B1 (en) 2017-05-22 2022-08-24 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
AU2018345647A1 (en) 2017-10-04 2020-04-16 Celgene Corporation Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
EP3833372A4 (en) * 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
MX2021012638A (es) * 2019-04-16 2022-01-04 Vivace Therapeutics Inc Compuestos biciclicos.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021102204A1 (en) * 2019-11-20 2021-05-27 Vivace Therapeutics, Inc. Heteroaryl compounds
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
KR102664454B1 (ko) * 2021-08-03 2024-05-09 한국생명공학연구원 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용
CN114681456A (zh) * 2022-02-23 2022-07-01 中山大学附属第六医院 Plx3397在结直肠癌的治疗中的用途
EP4703725A1 (en) 2024-08-29 2026-03-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Modulators of the mitotic cell cycle in cancer cells and uses thereof for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076595A1 (en) 2005-01-13 2006-07-20 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
JP2009535346A (ja) 2006-04-26 2009-10-01 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物及びそれによる治療方法
US20100016586A1 (en) 2006-05-12 2010-01-21 Myriad Genetics, Incorporated Therapeutic compounds and their use in cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
AU2004309420B2 (en) * 2003-12-23 2008-10-30 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
WO2007062338A2 (en) 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
CA2667345C (en) 2006-10-27 2016-03-22 Signal Pharmaceuticals, Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
ES2400006T3 (es) 2008-04-23 2013-04-04 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9512124B2 (en) * 2014-10-06 2016-12-06 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CN115131834A (zh) * 2015-08-13 2022-09-30 小米科技有限责任公司 移动设备及其屏幕模组、指纹采集方法、装置及电子设备
HUE056631T2 (hu) * 2016-04-01 2022-02-28 Signal Pharm Llc (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076595A1 (en) 2005-01-13 2006-07-20 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
JP2008526989A (ja) * 2005-01-13 2008-07-24 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法
JP2009535346A (ja) 2006-04-26 2009-10-01 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物及びそれによる治療方法
US20100016586A1 (en) 2006-05-12 2010-01-21 Myriad Genetics, Incorporated Therapeutic compounds and their use in cancer

Also Published As

Publication number Publication date
JP7014731B2 (ja) 2022-02-01
BR112018070163A2 (pt) 2019-01-29
MX2018011992A (es) 2019-01-24
KR20180126497A (ko) 2018-11-27
MX379513B (es) 2025-03-11
EA201892229A1 (ru) 2019-03-29
CN109069512A (zh) 2018-12-21
NZ746554A (en) 2023-03-31
EA039392B1 (ru) 2022-01-21
AU2017241837B2 (en) 2021-07-22
CN109069512B (zh) 2022-06-14
CA3018986A1 (en) 2017-10-05
JP2019510066A (ja) 2019-04-11
CL2018002787A1 (es) 2019-01-18
EP3436018A4 (en) 2019-11-13
WO2017173206A1 (en) 2017-10-05
IL262007B (en) 2022-12-01
IL262007A (en) 2018-10-31
IL262007B2 (en) 2023-04-01
SG10202009589UA (en) 2020-10-29
US20170281633A1 (en) 2017-10-05
SG11201808388QA (en) 2018-10-30
US10576085B2 (en) 2020-03-03
EP3436018A1 (en) 2019-02-06
AU2017241837A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
KR102356433B1 (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
AU2014253978B2 (en) Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
US9782427B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy
US10004735B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
ES2895419T3 (es) Formas sólidas de (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexan-1-carboxamida y métodos para su uso
TW201242601A (en) Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
CA2909579A1 (en) Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
EP3131550B1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy with a histone deacetylase inhibitor
HK1233943B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1233943A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629859B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ614493B2 (en) Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5